Holen Sie sich die Stockscreener-App
24.16
0.75%
0.18
Schlusskurs vom Vortag:
$23.98
Offen:
$24.1
24-Stunden-Volumen:
274.37K
Relative Volume:
0.83
Marktkapitalisierung:
$1.57B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-143.59M
KGV:
-8.5565
EPS:
-2.8236
Netto-Cashflow:
$-119.47M
1W Leistung:
-8.55%
1M Leistung:
-6.39%
6M Leistung:
+40.22%
1J Leistung:
+27.02%
1-Tages-Spanne:
$23.71
$24.62
1-Wochen-Bereich:
$23.15
$26.87
52-Wochen-Spanne:
$11.51
$29.80
Pharvaris Nv Stock (PHVS) Company Profile
Vergleichen Sie PHVS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PHVS
Pharvaris Nv
|
24.16 | 1.56B | 0 | -143.59M | -119.47M | -2.8236 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Pharvaris Nv Stock (PHVS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-10-09 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2025-06-11 | Eingeleitet | Guggenheim | Buy |
| 2025-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-09-25 | Eingeleitet | Wedbush | Outperform |
| 2023-08-15 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-10-05 | Eingeleitet | Bryan Garnier | Buy |
| 2022-09-13 | Fortgesetzt | JMP Securities | Mkt Outperform |
| 2022-08-23 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-22 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-05-25 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-03-02 | Eingeleitet | BofA Securities | Neutral |
| 2021-03-02 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-03-02 | Eingeleitet | Oppenheimer | Outperform |
| 2021-03-02 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Pharvaris Nv Aktie (PHVS) Neueste Nachrichten
Pharvaris (NASDAQ:PHVS) Rating Lowered to Sell at Wall Street Zen - Defense World
Pharvaris N.V. $PHVS Shares Bought by TFG Asset Management GP Ltd - MarketBeat
(PHVS) Movement Within Algorithmic Entry Frameworks - news.stocktradersdaily.com
Pharvaris N.V. (PHVS) Discusses Topline Data From RAPIDe-3 Phase III Study of Deucrictibant for Hereditary AngioedemaSlideshow (NASDAQ:PHVS) 2025-12-09 - Seeking Alpha
This Biotech Fund Just Made a $22 Million Bet on Pharvaris Stock — Is It a Buy? - AOL.com
Pharvaris’ Deucrictibant Provides Rapid Relief for HAE in Phase 3 RAPIDe-3 Trial - HCPLive
GENERAL ATLANTIC, L.P.'s Pharvaris NV(PHVS) Holding History - GuruFocus
Pharvaris (PHVS): Reassessing Valuation After Strong RAPIDe-3 Phase 3 Success in Hereditary Angioedema - Sahm
Pharvaris N.V. (PHVS) Price Target Increased by 20.90% to 45.73 - Nasdaq
Pharvaris (NASDAQ:PHVS) Given New $30.00 Price Target at Bank of America - MarketBeat
Why Pharvaris N.V. (9EN) stock could outperform next year2025 Retail Activity & Free Daily Entry Point Trade Alerts - Newser
Pharvaris (NASDAQ:PHVS) Price Target Raised to $30.00 at Bank of America - Defense World
B of A Securities Maintains Pharvaris N.V. (PHVS) Neutral Recommendation - Nasdaq
Guggenheim Maintains Pharvaris N.V. (PHVS) Buy Recommendation - Nasdaq
Oppenheimer Maintains Pharvaris N.V. (PHVS) Outperform Recommendation - Nasdaq
Officer Abele Files To Sell 4,109 Of Pharvaris NV [PHVS] - TradingView
Pharvaris N.V. (PHVS) Presents at BSI Clinical Immunology Professional Network (BSI-CIPN) Conference 2025Slideshow (NASDAQ:PHVS) 2025-12-04 - Seeking Alpha
Pharvaris Stock Gains on HAE Drug Meeting Late-Stage Study Goals - sharewise.com
Is Pharvaris N.V. stock undervalued vs historical averagesWeekly Market Report & Safe Capital Growth Tips - Newser
Pharvaris (NASDAQ:PHVS) Given "Buy" Rating at HC Wainwright - MarketBeat
Pharvaris (NASDAQ:PHVS) Sees Large Volume IncreaseShould You Buy? - MarketBeat
Pharvaris' Phase 3 Trial of Deucrictibant for HAE Attacks Confirms a Differentiated On-Demand Profile, Morgan Stanley Says - marketscreener.com
Will Pharvaris N.V. stock remain a Wall Street favoriteWeekly Trade Review & Free High Accuracy Swing Entry Alerts - Newser
A new trading data show Pharvaris NV (PHVS) is showing positive returns. - setenews.com
Morgan Stanley Raises Price Target on Pharvaris to $41 From $37, Keeps Overweight Rating - MarketScreener
Pharvaris (NASDAQ:PHVS) Sets New 1-Year HighWhat's Next? - MarketBeat
Is Pharvaris N.V. (9EN) stock undervalued after correctionBull Run & Technical Pattern Based Signals - Newser
Pharvaris’ (PHVS) Buy Rating Reaffirmed at HC Wainwright - Defense World
Can Pharvaris N.V. (9EN) stock survive global slowdownQuarterly Portfolio Report & Smart Investment Allocation Insights - Newser
What momentum indicators show for Pharvaris N.V. stockJuly 2025 Reactions & Free Reliable Trade Execution Plans - Newser
CEO Modig Files To Sell 109,583 Of Pharvaris NV [PHVS] - TradingView
Pharvaris NV Stock Analysis and ForecastAnalyst Downgrades & Ask Experts in Our Investment Forum - earlytimes.in
Leerink Partners raises Pharvaris stock price target to $38 on positive trial data - Investing.com India
Pharvaris (NASDAQ:PHVS) Shares Down 4.8%Time to Sell? - MarketBeat
Pharvaris’ oral deucrictibant hits endpoints in acute HAE trial - BioWorld MedTech
Pharvaris achieves primary goal in late-stage trial of deucrictibant for HAE - Seeking Alpha
Why Pharvaris Stock Is Soaring TodayPharvaris (NASDAQ:PHVS) - Benzinga
Pharvaris Shares Surge After Strong Phase 3 Results for Oral HAE Treatment - MSN
Pharvaris announces positive topline data from Rapide-3 pivotal study - marketscreener.com
Pharvaris Says Phase 3 Deucrictibant Trial Meets Endpoints in Hereditary Angioedema - marketscreener.com
Pharvaris Announces Positive Topline Data From Rapide-3 Pivotal Study - TradingView
PHVS: Deucrictibant showed rapid, significant efficacy and safety in HAE, supporting 2026 regulatory filings - TradingView
Pharvaris stock surges after positive HAE treatment study results By Investing.com - Investing.com Canada
Pharvaris stock surges after positive HAE treatment study results - Investing.com
Pharvaris Announces Positive Topline Data from RAPIDe-3 - GlobeNewswire
Pharvaris Pill Provides Rapid Relief In Patients With Rare Swelling Attacks, Data Shows - Sahm
Pharvaris N.V. (NASDAQ:PHVS) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
How Pharvaris N.V. stock compares to growth peersJuly 2025 Fed Impact & Weekly High Return Opportunities - Newser
Is Pharvaris N.V. (9EN) stock attractive for growth fundsIPO Watch & Free Weekly Chart Analysis and Trade Guides - Newser
How (PHVS) Movements Inform Risk Allocation Models - news.stocktradersdaily.com
Pharvaris Reports Q3 2025 Financial Results and Updates - MSN
Finanzdaten der Pharvaris Nv-Aktie (PHVS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.08%
0.91%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):